These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32567390)

  • 1.
    Benigni R; Bassan A; Pavan M
    Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):651-662. PubMed ID: 32567390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.
    Landry C; Kim MT; Kruhlak NL; Cross KP; Saiakhov R; Chakravarti S; Stavitskaya L
    Regul Toxicol Pharmacol; 2019 Dec; 109():104488. PubMed ID: 31586682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing best practise in the application of expert review of mutagenicity under ICH M7.
    Barber C; Amberg A; Custer L; Dobo KL; Glowienke S; Van Gompel J; Gutsell S; Harvey J; Honma M; Kenyon MO; Kruhlak N; Muster W; Stavitskaya L; Teasdale A; Vessey J; Wichard J
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):367-77. PubMed ID: 26248005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Consultancy Activity on In Silico Models for Genotoxic Prediction of Pharmaceutical Impurities.
    Pavan M; Kovarich S; Bassan A; Broccardo L; Yang C; Fioravanzo E
    Methods Mol Biol; 2016; 1425():511-29. PubMed ID: 27311479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the impact of expert knowledge on ICH M7 (Q)SAR predictions. Is expert review still needed?
    Jayasekara PS; Skanchy SK; Kim MT; Kumaran G; Mugabe BE; Woodard LE; Yang J; Zych AJ; Kruhlak NL
    Regul Toxicol Pharmacol; 2021 Oct; 125():105006. PubMed ID: 34273441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities.
    Sutter A; Amberg A; Boyer S; Brigo A; Contrera JF; Custer LL; Dobo KL; Gervais V; Glowienke S; van Gompel J; Greene N; Muster W; Nicolette J; Reddy MV; Thybaud V; Vock E; White AT; Müller L
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):39-52. PubMed ID: 23669331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico prediction of genotoxicity.
    Wichard JD
    Food Chem Toxicol; 2017 Aug; 106(Pt B):595-599. PubMed ID: 27979779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward regulatory acceptance and improving the prediction confidence of in silico approaches: a case study of genotoxicity.
    Tcheremenskaia O; Benigni R
    Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):987-1005. PubMed ID: 34078212
    [No Abstract]   [Full Text] [Related]  

  • 9. Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses.
    Amberg A; Beilke L; Bercu J; Bower D; Brigo A; Cross KP; Custer L; Dobo K; Dowdy E; Ford KA; Glowienke S; Van Gompel J; Harvey J; Hasselgren C; Honma M; Jolly R; Kemper R; Kenyon M; Kruhlak N; Leavitt P; Miller S; Muster W; Nicolette J; Plaper A; Powley M; Quigley DP; Reddy MV; Spirkl HP; Stavitskaya L; Teasdale A; Weiner S; Welch DS; White A; Wichard J; Myatt GJ
    Regul Toxicol Pharmacol; 2016 Jun; 77():13-24. PubMed ID: 26877192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure.
    Araya S; Lovsin-Barle E; Glowienke S
    Regul Toxicol Pharmacol; 2015 Nov; 73(2):515-20. PubMed ID: 26454093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of In Silico Methods for Regulatory Toxicological Assessment of Pharmaceutical Impurities.
    Kovarich S; Cappelli CI
    Methods Mol Biol; 2022; 2425():537-560. PubMed ID: 35188646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of in-house and off-the-shelf in silico models: implications on guidance for mutagenicity assessment.
    Jolly R; Ahmed KB; Zwickl C; Watson I; Gombar V
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):388-97. PubMed ID: 25656493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbamates and ICH M7 classification: Making use of expert knowledge.
    Hemingway R; Fowkes A; Williams RV
    Regul Toxicol Pharmacol; 2017 Jun; 86():392-401. PubMed ID: 28385577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.
    Ahlberg E; Amberg A; Beilke LD; Bower D; Cross KP; Custer L; Ford KA; Van Gompel J; Harvey J; Honma M; Jolly R; Joossens E; Kemper RA; Kenyon M; Kruhlak N; Kuhnke L; Leavitt P; Naven R; Neilan C; Quigley DP; Shuey D; Spirkl HP; Stavitskaya L; Teasdale A; White A; Wichard J; Zwickl C; Myatt GJ
    Regul Toxicol Pharmacol; 2016 Jun; 77():1-12. PubMed ID: 26879463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (Q)SAR assessments of potentially mutagenic impurities: a regulatory perspective on the utility of expert knowledge and data submission.
    Powley MW
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):295-300. PubMed ID: 25545315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of mutagenicity of chemical substances by (quantitative) structure-activity relationship.
    Honma M
    Genes Environ; 2020; 42():23. PubMed ID: 32626544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities.
    Valencia A; Prous J; Mora O; Sadrieh N; Valerio LG
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):427-34. PubMed ID: 24090816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico assessment of genotoxicity. Combinations of sensitive structural alerts minimize false negative predictions for all genotoxicity endpoints and can single out chemicals for which experimentation can be avoided.
    Benigni R
    Regul Toxicol Pharmacol; 2021 Nov; 126():105042. PubMed ID: 34506881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. It's difficult, but important, to make negative predictions.
    Williams RV; Amberg A; Brigo A; Coquin L; Giddings A; Glowienke S; Greene N; Jolly R; Kemper R; O'Leary-Steele C; Parenty A; Spirkl HP; Stalford SA; Weiner SK; Wichard J
    Regul Toxicol Pharmacol; 2016 Apr; 76():79-86. PubMed ID: 26785392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico Approaches in Predictive Genetic Toxicology.
    Sinha M; Dhawan A; Parthasarathi R
    Methods Mol Biol; 2019; 2031():351-373. PubMed ID: 31473971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.